biopharmaceutical development

Alpha Cognition is a commercial stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The company received FDA approval on July 26, 2024 of its New Drug Application for ZUNVEYL (benzgalantamine), previously known as ALPHA-1062 oral tablet formulation, for the treatment of mild-to-moderate Alzheimer's disease.

commercial manufacturingcommercial salespre-clinical development

CelaCare is a young biopharmaceutical company established from Harding University's College of Pharmacy. The company is engaged in the development of a portfolio of novel antimicrobial and immunotherapeutic products for mucosal and topical therapy based on its patent-protected technology.

antimicrobial and immunotherapeutic product developmentclinical development

Corium is a commercial-stage biopharmaceutical company advancing novel neuroscience therapies that provide clinicians with treatment options for patients, their families, and their caregivers. The company is dedicated to advancing innovative therapies that elevate standards of care, with therapeutic areas of focus including ADHD and Alzheimer's.

investigator initiated studiesmedical education grantsneuroscience therapies

Cumberland Pharmaceuticals Inc. is an innovation-driven biopharmaceutical company based in Nashville, Tennessee, and publicly listed on Nasdaq under CPIX. For over 25 years it has improved patient care through the delivery of high-quality prescription medicines, and it develops new therapies addressing significant unmet medical needs.

clinical trialsdrug development